Objective To investigate the therapeutic effect of mouse nerve growth factor (MNGF) on patients with profound sudden sensorineural hearing loss (SSNHL) based on a clinical trial. Methods A retrospective study was carried out among 53 patients with profound SSNHL treated in our Hospital from Dec., 2013 to Dec., 2015 as treating group (TG), with those 45 hospitalized cases treated from Jun., 2011 to Jun., 2013 in our Hospital as controlling group (CG). Cases in TG were treated by a combined therapy with MNGF plus the routine therapy composed of batroxobin, ginkgodipyidamolum, methylprednisolone sodium succinate, and hyperbaric oxygen therapy, while those in CG were treated only by the routine therapy as that for TG, with the therapeutic course lasted for 2 weeks foe both groups. Then, a comparative analysis was made between these 2 groups to evaluate the therapeutic effect on the condition in these two groups according to their changes in pure tone audiogram and grading of tinnitus before and after treatment. Results The total effective rate was 81.1% and 66.7% respectively for hearing improvement in the two groups, with no statistical significance in the difference between them (χ2=2.068, P=0.102). The effective rate of tinnitus improvement in TG was 86.0%, while it was 75.6% in CG (χ2=1.601, P=0.206), also with no statistical significance in the difference between the two groups. Conclusion Although mouse nerve growth factor can improve the hearing loss of patients with profound SSNHL to some extent, it may not be so effective to improve the overall therapeutic effect on patients with such a condition.%目的：观察鼠神经生长因子治疗全聋型突发性聋的临床疗效。方法回以2013年12月至2015年12月期间我科住院治疗的全聋型突发性聋患者为治疗组，应用鼠神经生长因子+巴曲酶+银杏达莫+甲泼尼龙+高压氧方案治疗；以2011年6月至2013年6月收治的全聋型突发性聋45例作为对照组，治疗方案中除无鼠神经生长因子外，余均和治疗组相同；疗程均为2周。采用回顾性研究方法比较分析两组治疗前后的平均听阈差及耳鸣症状分级差以评价疗效。结果治疗组患者听力改善总有效率为81.1%，照组为66.7%，组间差异无统计学意义（χ2=2.068，P=0.102）；治疗组耳鸣改善率为86.0%，对照组为75.6%，差异无统计学意义（χ2=1.601，P=0.206）。结论鼠神经生长因子并不能提高全聋型突发性聋的整体效果。
展开▼
